Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1989 Apr 15;298(6679):985–990. doi: 10.1136/bmj.298.6679.985

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.

A G Jolley 1, S R Hirsch 1, A McRink 1, R Manchanda 1
PMCID: PMC1836296  PMID: 2567190

Abstract

A study was conducted to investigate a novel approach to the prophylaxis of schizophrenic relapse. The treatment strategy comprised brief intermittent courses of neuroleptic agents begun as soon as non-psychotic symptoms believed to be early signs of relapse appeared. Fifty four stable, remitted outpatients meeting the American Psychiatric Association's DSM-III criteria for schizophrenia were randomised double blind to receive brief intermittent treatment with either active or placebo depot neuroleptic injections. Only three patients given placebo injections and two controls were admitted to hospital during one year of follow up. Eight (30%) of the patients given placebo injections and only 2 (7%) of the controls, however, had a recurrence of schizophrenic symptoms. Patients given placebo injections experienced fewer extrapyramidal side effects and showed a trend towards a reduction in tardive dyskinesia. Dysphoric and neurotic symptoms were identified before eight out of 11 relapses, and these symptoms were more frequent in patients given placebo depot injections. These results suggest a viable but not necessarily better alternative to continuous oral or depot treatment for less ill, chronic, stabilised schizophrenics based on the early treatment of putative prodromal symptoms of relapse.

Full text

PDF
985

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carpenter W. T., Jr, Heinrichs D. W., Hanlon T. E. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry. 1987 Nov;144(11):1466–1470. doi: 10.1176/ajp.144.11.1466. [DOI] [PubMed] [Google Scholar]
  2. Davis J. M. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry. 1976 Jul;33(7):858–861. doi: 10.1001/archpsyc.1976.01770070088010. [DOI] [PubMed] [Google Scholar]
  3. Derogatis L. R., Lipman R. S., Covi L. SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacol Bull. 1973 Jan;9(1):13–28. [PubMed] [Google Scholar]
  4. Docherty J. P., Van Kammen D. P., Siris S. G., Marder S. R. Stages of onset of schizophrenic psychosis. Am J Psychiatry. 1978 Apr;135(4):420–426. doi: 10.1176/ajp.135.4.420. [DOI] [PubMed] [Google Scholar]
  5. Endicott J., Spitzer R. L., Fleiss J. L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976 Jun;33(6):766–771. doi: 10.1001/archpsyc.1976.01770060086012. [DOI] [PubMed] [Google Scholar]
  6. Falloon I., Watt D. C., Shepherd M. The social outcome of patients in a trial of long-term continuation therapy in schizophrenia: pimozide vs. fluphenazine. Psychol Med. 1978 May;8(2):265–274. doi: 10.1017/s0033291700014318. [DOI] [PubMed] [Google Scholar]
  7. Heinrichs D. W., Cohen B. P., Carpenter W. T., Jr Early insight and the management of schizophrenic decompensation. J Nerv Ment Dis. 1985 Mar;173(3):133–138. doi: 10.1097/00005053-198503000-00001. [DOI] [PubMed] [Google Scholar]
  8. Herz M. I., Melville C. Relapse in schizophrenia. Am J Psychiatry. 1980 Jul;137(7):801–805. doi: 10.1176/ajp.137.7.801. [DOI] [PubMed] [Google Scholar]
  9. Herz M. I., Szymanski H. V., Simon J. C. Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry. 1982 Jul;139(7):918–922. doi: 10.1176/ajp.139.7.918. [DOI] [PubMed] [Google Scholar]
  10. Hirsch S. R. Depression 'revealed' in schizophrenia. Br J Psychiatry. 1982 Apr;140:421–423. doi: 10.1192/bjp.140.4.421. [DOI] [PubMed] [Google Scholar]
  11. Jeste D. V., Potkin S. G., Sinha S., Feder S., Wyatt R. J. Tardive dyskinesia--reversible and persistent. Arch Gen Psychiatry. 1979 May;36(5):585–590. doi: 10.1001/archpsyc.1979.01780050095012. [DOI] [PubMed] [Google Scholar]
  12. Johnson D. A., Pasterski G., Ludlow J. M., Street K., Taylor R. D. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983 May;67(5):339–352. doi: 10.1111/j.1600-0447.1983.tb00351.x. [DOI] [PubMed] [Google Scholar]
  13. Johnson D. A. Studies of depressive symptoms in schizophrenia. Br J Psychiatry. 1981 Aug;139:89–101. doi: 10.1192/bjp.139.2.89. [DOI] [PubMed] [Google Scholar]
  14. Kane J. M., Rifkin A., Woerner M., Reardon G., Sarantakos S., Schiebel D., Ramos-Lorenzi J. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry. 1983 Aug;40(8):893–896. doi: 10.1001/archpsyc.1983.01790070083010. [DOI] [PubMed] [Google Scholar]
  15. Kane J. M., Smith J. M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982 Apr;39(4):473–481. doi: 10.1001/archpsyc.1982.04290040069010. [DOI] [PubMed] [Google Scholar]
  16. Knights A., Hirsch S. R. "Revealed" Depression and drug treatment for schizophrenia. Arch Gen Psychiatry. 1981 Jul;38(7):806–811. doi: 10.1001/archpsyc.1981.01780320086010. [DOI] [PubMed] [Google Scholar]
  17. Knights A., Okasha M. S., Salih M. A., Hirsch S. R. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. Br J Psychiatry. 1979 Dec;135:515–523. doi: 10.1192/bjp.135.6.515. [DOI] [PubMed] [Google Scholar]
  18. Krawiecka M., Goldberg D., Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand. 1977 Apr;55(4):299–308. doi: 10.1111/j.1600-0447.1977.tb00174.x. [DOI] [PubMed] [Google Scholar]
  19. Leff J., Kuipers L., Berkowitz R., Eberlein-Vries R., Sturgeon D. A controlled trial of social intervention in the families of schizophrenic patients. Br J Psychiatry. 1982 Aug;141:121–134. doi: 10.1192/bjp.141.2.121. [DOI] [PubMed] [Google Scholar]
  20. Marder S. R., Van Putten T., Mintz J., Lebell M., McKenzie J., May P. R. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry. 1987 Jun;44(6):518–521. doi: 10.1001/archpsyc.1987.01800180028005. [DOI] [PubMed] [Google Scholar]
  21. McCreadie R. G., Mackie M., Wiles D. H., Jorgensen A., Hansen V., Menzies C. Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. Br J Psychiatry. 1984 Jun;144:625–629. doi: 10.1192/bjp.144.6.625. [DOI] [PubMed] [Google Scholar]
  22. Owens D. G., Johnstone E. C., Frith C. D. Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry. 1982 Apr;39(4):452–461. doi: 10.1001/archpsyc.1982.04290040052008. [DOI] [PubMed] [Google Scholar]
  23. Smith J. M., Kucharski L. T., Eblen C., Knutsen E., Linn C. An assessment of tardive dyskinesia in schizophrenic outpatients. Psychopharmacology (Berl) 1979 Jun 28;64(1):99–104. doi: 10.1007/BF00427353. [DOI] [PubMed] [Google Scholar]
  24. Van Putten T., May R. P. "Akinetic depression" in schizophrenia. Arch Gen Psychiatry. 1978 Sep;35(9):1101–1107. doi: 10.1001/archpsyc.1978.01770330075006. [DOI] [PubMed] [Google Scholar]
  25. Wistedt B., Jørgensen A., Wiles D. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology (Berl) 1982;78(4):301–304. doi: 10.1007/BF00433729. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES